Abbott Laboratories (ABT) Competitors

DexCom (NASDAQ:DXCM) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

Which has higher valuation & earnings, DXCM or ABT?

Abbott Laboratories has higher revenue and earnings than DexCom. Abbott Laboratories is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$4.03B	7.30	$576.20M	$1.44	52.14
Abbott Laboratories	$41.95B	5.45	$13.40B	$7.98	16.47

Does the media prefer DXCM or ABT?

In the previous week, Abbott Laboratories had 8 more articles in the media than DexCom. MarketBeat recorded 43 mentions for Abbott Laboratories and 35 mentions for DexCom. Abbott Laboratories' average media sentiment score of 1.51 beat DexCom's score of 1.23 indicating that Abbott Laboratories is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DexCom	23 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Abbott Laboratories	38 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Do institutionals & insiders hold more shares of DXCM or ABT?

97.8% of DexCom shares are owned by institutional investors. Comparatively, 75.2% of Abbott Laboratories shares are owned by institutional investors. 0.3% of DexCom shares are owned by company insiders. Comparatively, 0.5% of Abbott Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Which has more risk and volatility, DXCM or ABT?

DexCom has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.

Do analysts prefer DXCM or ABT?

DexCom currently has a consensus price target of $99.89, indicating a potential upside of 33.05%. Abbott Laboratories has a consensus price target of $144.47, indicating a potential upside of 9.89%. Given DexCom's stronger consensus rating and higher probable upside, equities research analysts clearly believe DexCom is more favorable than Abbott Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	0 Sell rating(s)	4 Hold rating(s)	15 Buy rating(s)	3 Strong Buy rating(s)	2.95
Abbott Laboratories	0 Sell rating(s)	4 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.91

Is DXCM or ABT more profitable?

Abbott Laboratories has a net margin of 32.43% compared to DexCom's net margin of 13.29%. DexCom's return on equity of 30.41% beat Abbott Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DexCom	13.29%	30.41%	10.08%
Abbott Laboratories	32.43%	18.32%	10.71%

Summary

Abbott Laboratories beats DexCom on 9 of the 17 factors compared between the two stocks.